IE 11 is not supported. For an optimal experience visit our site on another browser.

Cyclacel Pharmaceuticals Inc. is Today's Focus Stock on MicroStockProfit.com

DALLAS, May 10, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. (Nasdaq:CYCC). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
/ Source: GlobeNewswire

DALLAS, May 10, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. (Nasdaq:CYCC). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at:

Cyclacel (CYCC) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The Company focuses primarily on the development of orally available anticancer agents that target the cell cycle with the aim of slowing the progression or shrinking the size of tumors. CYCC's ALIGN Pharmaceuticals subsidiary markets directly in the United States Xclair Cream for radiation dermatitis, Numoisyn Liquid and Numoisyn Lozenges for xerostomia.

This newsletter has been helping traders make great investment decisions on CYCC; click here for a 25% discount offer.

In the report, the analyst notes:

"CYCC shares went up on Monday amid expectations of results at this year's American Society of Clinical Oncology (ASCO) meeting. Eisai Co. is scheduled to report results from its DACO-016 phase III study of Dacogen (decitabine) as a frontline treatment for elderly patients with acute myelogenous leukemia (AML). CYCC's sapacitabine shares a similar therapeutic indication."

"In January of this year, CYCC launched enrollment of the SEAMLESS pivotal phase III trial, evaluating sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly-diagnosed AML who are not candidates for intensive induction chemotherapy."

To read the entire report visit:

See what investors are saying about CYCC at

Get breaking news on CYCC at

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit:

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson info@microstockprofit.com 1-888-307-2850